Julie Brown Buys 5 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK - Get Free Report) insider Julie Brown bought 5 shares of the business's stock in a transaction dated Monday, April 13th. The stock was purchased at an average price of GBX 2,171 per share, for a total transaction of £108.55.

• Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

Julie Brown also recently made the following trade(s):

• On Tuesday, February 10th, Julie Brown bought 6 shares of GSK stock. The stock was purchased at an average price of GBX 2,179 per share, for a total transaction of £130.74.

GSK Stock Up 0.9%

Shares of GSK stock opened at GBX 2,190 on Wednesday. The company's 50 day moving average price is GBX 2,110.80 and its 200-day moving average price is GBX 1,890.47. GSK plc has a 52-week low of GBX 1,263.50 and a 52-week high of GBX 2,282. The stock has a market capitalization of £87.53 billion, a price-to-earnings ratio of 15.78, a P/E/G ratio of 1.24 and a beta of 0.35. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82.

• ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities research analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Key GSK News

---

---

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Positive Phase I BEHOLD‑1 data for Mo‑Rez in endometrial and ovarian cancer — early results were reported as encouraging, which boosts GSK’s oncology pipeline prospective value and investor sentiment. GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
• Positive Sentiment: Share buyback continued: GSK repurchased 325,000 ordinary shares (13 April), expanding treasury stock and lifting treasury holdings to ~6.36% of voting rights — buybacks reduce float and are a direct capital-return/earnings-per-share support. GSK Expands Treasury Stock with Latest Share Buyback Tranche GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
• Positive Sentiment: Jefferies reaffirmed a "buy" rating with a GBX 2,500 price target — a favorable broker upgrade/confirmation that can attract momentum and institutional interest. Broker Views
• Positive Sentiment: Insiders/executives buying: a disclosed executive share acquisition under GSK’s reward plan and an insider (Julie Brown) bought 5 shares at ~GBX 2,171 — modest but supportive signals that management has some conviction in the stock. GSK Executives Acquire Shares Under Company Reward Plan
• Neutral Sentiment: Overall analyst consensus remains mixed to neutral — an aggregate "Hold" rating was reported from brokerages, indicating some caution despite the positives above. GSK Receives Average Rating of "Hold" from Brokerages

Analyst Upgrades and Downgrades

• Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging

GSK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research note on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft raised their price target on GSK from GBX 1,600 to GBX 1,675 and gave the stock a "hold" rating in a research note on Thursday, January 15th. Shore Capital Group reaffirmed a "buy" rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup raised their price target on GSK from GBX 1,900 to GBX 2,250 and gave the stock a "buy" rating in a research note on Monday, February 9th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a GBX 2,500 price target on shares of GSK in a research note on Tuesday. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, GSK currently has a consensus rating of "Hold" and a consensus price target of GBX 2,023.57.

Check Out Our Latest Report on GSK

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

See Also

• Five stocks we like better than GSK

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].